NDAIMPLANTATIONIMPLANT
Approved
Mar 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
4/8 — Partial
VIADUR (leuprolide acetate) by Johnson & Johnson is acetate, a gnrh agonist, acts as an inhibitor of gonadotropin secretion. Approved for prostate cancer, central precocious puberty, endometriosis. First approved in 2000.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIADUR is a subcutaneous implant formulation of leuprolide acetate, a GnRH agonist that suppresses gonadotropin secretion and reduces hormone-dependent tumor growth. It is indicated for prostate cancer, central precocious puberty, and endometriosis. The drug works by initially stimulating then continuously suppressing pituitary gonadotropins, leading to decreased gonadal steroid production and atrophy of reproductive tissues.
LOE Approaching
As VIADUR approaches loss of exclusivity, commercial team size and promotional activities are expected to decline, creating career instability for brand-focused roles.
Mechanism of Action
acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal studies indicate that following an initial stimulation, continuous administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect was reversible upon discontinuation…
Indications (3)
Worked on VIADUR at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.